Moberg Pharma AB (publ) (MOB.ST)
SEK 7.84
(-0.19%)
SEK 7.84
(-0.19%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -55.81 Million SEK | 52.99% |
| 2022 | -118.74 Million SEK | -21.14% |
| 2021 | -98.02 Million SEK | -724.35% |
| 2020 | -11.89 Million SEK | 0.0% |
| 2018 | 484.43 Million SEK | 2.41% |
| 2017 | 473.05 Million SEK | -6.07% |
| 2016 | 503.63 Million SEK | 1318.78% |
| 2015 | -41.32 Million SEK | 8.37% |
| 2014 | -45.09 Million SEK | -1366.06% |
| 2013 | 3.56 Million SEK | 126.54% |
| 2012 | -13.42 Million SEK | 81.87% |
| 2011 | -74.05 Million SEK | -2736.35% |
| 2010 | -2.61 Million SEK | 92.03% |
| 2009 | -32.77 Million SEK | -67.86% |
| 2008 | -19.52 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -34.2 Million SEK | 38.72% |
| 2024 Q2 | -321.96 Million SEK | -841.26% |
| 2023 Q2 | -47.52 Million SEK | 40.36% |
| 2023 Q3 | -97.7 Million SEK | -105.61% |
| 2023 Q4 | -55.81 Million SEK | 42.87% |
| 2023 FY | -55.81 Million SEK | 52.99% |
| 2023 Q1 | -79.67 Million SEK | 32.9% |
| 2022 Q3 | -140.68 Million SEK | 10.19% |
| 2022 FY | -118.74 Million SEK | -21.14% |
| 2022 Q4 | -118.74 Million SEK | 15.59% |
| 2022 Q1 | -70.18 Million SEK | 28.4% |
| 2022 Q2 | -156.64 Million SEK | -123.18% |
| 2021 Q2 | -108.86 Million SEK | 5.82% |
| 2021 Q4 | -98.02 Million SEK | 7.6% |
| 2021 FY | -98.02 Million SEK | -724.35% |
| 2021 Q1 | -115.58 Million SEK | -872.06% |
| 2021 Q3 | -106.09 Million SEK | 2.55% |
| 2020 Q3 | 1.56 Million SEK | 0.0% |
| 2020 Q1 | -15.02 Million SEK | 73.92% |
| 2020 FY | -11.89 Million SEK | 0.0% |
| 2020 Q4 | -11.89 Million SEK | -858.84% |
| 2019 Q4 | -57.62 Million SEK | 93.12% |
| 2019 Q1 | -831.76 Million SEK | -271.7% |
| 2019 Q2 | -830.19 Million SEK | 0.19% |
| 2019 Q3 | -837.73 Million SEK | -0.91% |
| 2018 Q2 | 555.67 Million SEK | 0.64% |
| 2018 FY | 484.43 Million SEK | 2.41% |
| 2018 Q4 | 484.43 Million SEK | -10.04% |
| 2018 Q3 | 538.52 Million SEK | -3.09% |
| 2018 Q1 | 552.15 Million SEK | 16.72% |
| 2017 Q2 | 631.91 Million SEK | 7.04% |
| 2017 Q1 | 590.32 Million SEK | 17.21% |
| 2017 FY | 473.05 Million SEK | -6.07% |
| 2017 Q4 | 473.05 Million SEK | -10.16% |
| 2017 Q3 | 526.53 Million SEK | -16.68% |
| 2016 Q2 | 149.33 Million SEK | 29.49% |
| 2016 Q3 | 327.36 Million SEK | 119.21% |
| 2016 Q4 | 503.63 Million SEK | 53.85% |
| 2016 FY | 503.63 Million SEK | 1318.78% |
| 2016 Q1 | 115.32 Million SEK | 379.08% |
| 2015 Q4 | -41.32 Million SEK | -345.07% |
| 2015 Q3 | 16.86 Million SEK | -67.1% |
| 2015 FY | -41.32 Million SEK | 8.37% |
| 2015 Q1 | 17.79 Million SEK | 139.46% |
| 2015 Q2 | 51.25 Million SEK | 188.06% |
| 2014 Q4 | -45.09 Million SEK | -2582.75% |
| 2014 Q3 | -1.68 Million SEK | -114.93% |
| 2014 Q1 | 55.21 Million SEK | 1449.97% |
| 2014 Q2 | 11.25 Million SEK | -79.61% |
| 2014 FY | -45.09 Million SEK | -1366.06% |
| 2013 Q1 | 53.37 Million SEK | 497.61% |
| 2013 Q3 | 15.18 Million SEK | -72.85% |
| 2013 FY | 3.56 Million SEK | 126.54% |
| 2013 Q4 | 3.56 Million SEK | -76.54% |
| 2013 Q2 | 55.92 Million SEK | 4.78% |
| 2012 Q4 | -13.42 Million SEK | 79.62% |
| 2012 FY | -13.42 Million SEK | 81.87% |
| 2012 Q3 | -65.87 Million SEK | -9.5% |
| 2012 Q2 | -60.15 Million SEK | -29.33% |
| 2012 Q1 | -46.51 Million SEK | 37.18% |
| 2011 FY | -74.05 Million SEK | -2736.35% |
| 2011 Q2 | -53.55 Million SEK | -4308.73% |
| 2011 Q4 | -74.05 Million SEK | -62.55% |
| 2011 Q3 | -45.55 Million SEK | 14.93% |
| 2011 Q1 | 1.27 Million SEK | 148.74% |
| 2010 FY | -2.61 Million SEK | 92.03% |
| 2010 Q4 | -2.61 Million SEK | 0.0% |
| 2009 FY | -32.77 Million SEK | -67.86% |
| 2008 FY | -19.52 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | -190.054% |
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | -91.814% |
| BioGaia AB (publ) | -1.53 Billion SEK | 96.365% |
| Enzymatica AB (publ) | 17.73 Million SEK | 414.698% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | -876.351% |
| Gabather AB (publ) | -1.11 Million SEK | -4906.099% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | 415.623% |
| Nanexa AB (publ) | -61.13 Million SEK | 8.699% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | -264.752% |
| ODI Pharma AB | -2.63 Million SEK | -2015.997% |
| Orexo AB (publ) | 302.8 Million SEK | 118.434% |
| Probi AB (publ) | -275.85 Million SEK | 79.765% |
| Swedencare AB (publ) | 1.42 Billion SEK | 103.927% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 100.285% |
| Toleranzia AB | -17.45 Million SEK | -219.801% |
| Vivesto AB | -1.29 Million SEK | -4196.998% |